Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 5,351 matching trials from the live ClinicalTrials.gov search.
Filters: Milwaukee, Wisconsin Clear all
Active, not recruiting Phase 2 Interventional

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Guselkumab, Golimumab, JNJ-78934804, Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
63
States / cities
Arcadia, California • Coronado, California • Lancaster, California + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients

NCT02238925
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
Interventions
CPX-351
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Indianapolis, Indiana • Westwood, Kansas • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 31, 2026, 12:45 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting

NCT04501952
View directory record Official record
Conditions
COVID-19
Interventions
RDV, Placebo to Match RDV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
92
States / cities
Chandler, Arizona • Tucson, Arizona • Eureka, California + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 31, 2026, 12:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study for the Assessment of the Quality of Echocardiographic Clips.

NCT05090748
View directory record Official record
Conditions
Cardiac Disease
Interventions
Echocardiographic.
Device
Lead sponsor
UltraSight
Industry
Eligibility
18 Years to 120 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Chicago, Illinois • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Not applicable Interventional

Prevention of HIV Infection in High-Risk Social Networks of African American Men Who Have Sex With Men (MSM)

NCT01825252
View directory record Official record
Conditions
HIV
Interventions
Social Network Intervention, Counsel, Test, and Treat
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Male only
Enrollment
856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Cleveland, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension

NCT01027949
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Oral Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors

NCT00053352
View directory record Official record
Conditions
Childhood Embryonal Tumor, Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Childhood Teratoma, Ovarian Embryonal Carcinoma, Ovarian Yolk Sac Tumor, Stage II Malignant Testicular Germ Cell Tumor, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Ovarian Germ Cell Tumor, Stage III Malignant Testicular Germ Cell Tumor, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIC Ovarian Germ Cell Tumor, Testicular Choriocarcinoma and Yolk Sac Tumor, Testicular Embryonal Carcinoma
Interventions
conventional surgery, cisplatin, etoposide, bleomycin sulfate, laboratory biomarker analysis
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
112
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 98 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 31, 2026, 12:45 AM EDT
Suspended Phase 2Phase 3 Interventional

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

NCT04402788
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
411
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 296 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma

NCT00003573
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
filgrastim, cisplatin, cyclophosphamide, etoposide, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
94
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 31, 2026, 12:45 AM EDT
Terminated Phase 4 Interventional Results available

Post-Approval Study of the NexStent Carotid Stent System and the FilterWire EZ Embolic Protection System: SONOMA

NCT00478673
View directory record Official record
Conditions
Carotid Stenosis
Interventions
NexStent Carotid Stent System (Monorail Delivery System), FilterWire EZ™ Embolic Protection System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
62
States / cities
Huntsville, Alabama • Phoenix, Arizona • Bakersfield, California + 54 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer

NCT01086605
View directory record Official record
Conditions
Breast Cancer
Interventions
pixantrone dimaleate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
230
States / cities
Fort Collins, Colorado • Hartford, Connecticut • Honolulu, Hawaii + 140 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 31, 2026, 12:45 AM EDT
Active, not recruiting No phase listed Observational

Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma

NCT03896620
View directory record Official record
Conditions
Sarcoma
Interventions
Preoperative RT, Postoperative RT, Chemotherapy, Surgery
Device · Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01484496
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, Belimumab 200 mg SC, Standard therapy
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
82
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718103
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
41
States / cities
Alabaster, Alabama • Mobile, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 31, 2026, 12:45 AM EDT
Active, not recruiting Not applicable Interventional

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

NCT02400190
View directory record Official record
Conditions
Breast Neoplasms
Interventions
endocrine therapy alone without radiotherapy
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
50 Years to 69 Years · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
13
States / cities
Stanford, California • New Haven, Connecticut • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 31, 2026, 12:45 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Durvalumab, Tremelimumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
34
States / cities
Tucson, Arizona • Santa Rosa, California • New Haven, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Not applicable Interventional Results available

Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System

NCT04580160
View directory record Official record
Conditions
May-Thurner Syndrome, Deep Vein Thrombosis, Chronic Venous Insufficiency
Interventions
Duo Venous Stent System
Device
Lead sponsor
Vesper Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
28
States / cities
Orange, California • Palo Alto, California • Darien, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study Evaluating Photobiomodulation Therapy for Diabetic Macular Edema

NCT03866473
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Retilux, Sham Light Device
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Huntington Beach, California • Oakland, California • Santa Barbara, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2022 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety Study of Plecanatide

NCT02706483
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Plecanatide
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
204
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 200 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 3 Interventional

Safety of Estrogens in Lupus: Birth Control Pills

NCT00000420
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Ortho-Novum 777
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
15
States / cities
Los Angeles, California • Chicago, Illinois • Shreveport, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 31, 2026, 12:45 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets, Etavopivat Tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 31, 2026, 12:45 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Study of Emapalumab for Pediatric Aplastic Anemia

NCT06430788
View directory record Official record
Conditions
Aplastic Anemia, Cytopenia, Hypocellular Marrow
Interventions
Emapalumab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
0 Years to 25 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
6
States / cities
New York, New York • Cincinnati, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 31, 2026, 12:45 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

NCT03793179
View directory record Official record
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Pemetrexed, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1081
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 694 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 12:45 AM EDT
Completed Phase 1 Interventional Results available

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

NCT04047862
View directory record Official record
Conditions
Locally Advanced and Metastatic Solid Tumors
Interventions
Ociperlimab, Tislelizumab, Pemetrexed, Paclitaxel, Nab paclitaxel, Carboplatin, Cisplatin, Etoposide, 5fluorouracil, Oxaliplatin, Capecitabine
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
11
States / cities
Phoenix, Arizona • Fort Myers, Florida • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 31, 2026, 12:45 AM EDT